Figure 1. Re-iterative progress in enhancing the efficacy of adoptive CD8⁺ T cell therapy for the treatment of melanoma using the pmel-1 mouse model.

The use of alternative γ_c cytokines or less differentiated T cell subsets has resulted in progressive improvements in the therapeutic efficacy of tumor-reactive CD8⁺ T cells, thus providing for effective tumor destruction with the transfer of limited numbers of cells. IL, interleukin; T_SCM, T memory stem cell.